[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570270":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":44,"responsibleParty":65,"collaborators":67,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":26,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":26,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Shanghai Jiao Tong University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Reduced dose of post-transplantation cyclophosphamide","EXPERIMENTAL","study group",[13],"Drug: reduced-dose PTCy",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard-dose PTCy","ACTIVE_COMPARATOR","Patients receiving standard dose of post-transplantation cyclophosphamide",[19],"Drug: Standard dose PTCY",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","reduced-dose PTCy","Patients receiving reduced dose of PTCy at 35mg.kg on day +3 and +4 together with tacrolimus starting from day+5 and single dose of anti-thymoglobin (ATG) 2.5mg\u002Fkg at 72 hours after documentation of neutrophil engraftment.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Standard dose PTCY","Patients receiving standard dose PTCy at 50mg\u002Fkg on day +3 and +4 with tacrolimus starting from day +5 and single dose of anti-thymoglobin at 2.5mg\u002Fkg 72 hours after documentation of neutrophil engraftment.",[15],[32],{"name":33,"affiliation":34,"role":35},"Jiong HU","Ruijin Hospital","PRINCIPAL_INVESTIGATOR",[37,41],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","86-13764313546","hj10709@rjh.com.cn",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":26},"Li-ning Wang","86-21-64370045",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Ruijin hsopital","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":54,"coordinates":55},"Point",[56,57],121.45806,31.22222,{"lat":57,"lon":56},[60,63,64],{"name":61,"role":38,"phone":43,"phoneExt":62,"email":40},"JIong HU","601878",{"name":42,"role":38,"phone":26,"phoneExt":26,"email":26},{"name":61,"role":35,"phone":26,"phoneExt":26,"email":26},{"type":35,"investigatorFullName":33,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Head, Blood & Marrow Transplantation Center, Rui Jin Hospital",[68],{"name":69,"class":6},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","100570270","phase-3-study-comparing-reduced-versus-standard-dose-post-transplantation-cyclophosphamide-in-combination-with-post-engraftment-anti-thymoglobin-as-graft-versus-host-disease-prophylaxis-in-alternative-donor-peripheral-stem-cell-transplantation-100570270",false,"NCT06705062","Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation","A Multi-center Randomized Clinical Study Comparing Reduced-dose (35mg\u002Fkg) Versus Standard Dose (50mg\u002Fkg) Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin (ATG) and Tacrolimus and Post-engraftment Anti-thymoglobin as Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergo Alternative Donor Peripheral Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. patients undergo allo-HSCT with matched unrelated donor or haplo-identical donor;\n2. normal organ function (creatinine clearance ≥ 50ml\u002Fmin\u002F1.73m2 or creatinine ≤2mg\u002Fd(or 177μmol\u002FL); no hepatic abnormal (ALT or AST≤2.5xN; TBil≤1.5XN); Normal pulmonary function (FEV1、 FVC、DLCO≥80%); normal cardiac function (EFS ≥50%);\n3. ECOG: 0-2;\n4. Life expectation ≥3 months;\n5. Informed consent provided.\n\nExclusion Criteria:\n\n1. Pregnancies\n2. active hepatitis (HBV-DNA≥1×103 copies\u002Fml);\n3. active infection require anti-biotics;\n4. HIV infection","ALL","18 Years","55 Years",{"count":81,"type":82},316,"ESTIMATED","INTERVENTIONAL",[85],"PHASE3","This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg\u002Fkg combined with tacrolimus and post-engraftment low dose anti-thymoglobin (ATG) as graft versus host disease (GVHD) prophylaxis in patients undergoing allogeneic stem cell transplantation from alternative donor.",[88,89],"Allogeneic Hematopoietic Cell Transplant","Graft Versus Host Disease",[91,92,93,94],"post-transplantation cyclophosphamide","prophylaxis","reduced dose","graft versus host disease","2026-03-15",{"date":97,"type":98},"2026-03-17","ACTUAL",{"date":100,"type":98},"2025-01-01",{"date":102,"type":82},"2028-07-01",{"name":5,"class":6},1]